| Value | ₹3.06 Cr |
|---|
BSE filing, NSE: MACINTR. Summary written from the filing by ALFA Finder's alert engine.
Astal Laboratories Ltd: key numbers
- Share price
- ₹61.70
- Market cap
- ₹260.5 Cr
- Revenue (annual)
- ₹156.0 Cr
- Net profit (annual)
- ₹8.12 Cr
- P/E (TTM)
- 26.8×Sector 45.0×
- Promoter holding
- 4.59%+0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astal Laboratories Ltd
All →Astal Laboratories Other Announcement
Astal Laboratories submitted the Regulation 74(5) certificate from its Registrar for the quarter ended September 30, 2026, confirming the dematerialization activities.
Astal Laboratories Other Announcement
Astal Laboratories' material subsidiary, Sriven Pharmachem India, appointed new Internal, Cost, and Secretarial Auditors. The appointments were approved during the subsidiary's board meeting on September 28, 2026.
Astal Laboratories Management Change
Astal Laboratories Limited has appointed Ms. Ambika Kedia as Company Secretary of its material wholly-owned subsidiary, Sriven Pharmachem India Private Limited. The appointment is effective from September 28, 2026.
Astal Laboratories Annual General Meeting
Astal Laboratories held its 33rd Annual General Meeting on September 29, 2026. Members transacted business regarding financial statements and the re-appointment of a director.
Astal Laboratories Promoter Buying: ₹0.2 Cr
Promoter Aceso Research Labs LLP acquired 25,417 equity shares of Astal Laboratories Ltd via market purchase, increasing their stake from 4.53% to 4.59%.
- Value
- ₹0.20 Cr
- Promoter stake change
- +0.06%
Astal Laboratories Promoter Buying
Astal Laboratories' promoter ACESO Research Labs LLP bought equity shares on BSE under a SEBI PIT disclosure. The open-market purchase signals promoter confidence.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr